ストックスクリーナーアプリを入手
3.11
2.20%
-0.07
プレマーケット:
3.14
0.03
+0.96%
前日終値:
$3.18
開ける：
$3.18
24時間の取引高:
22.08M
Relative Volume:
1.44
時価総額：
$1.65B
収益：
$66.41M
当期純損益:
$-559.78M
株価収益率:
-2.5869
EPS:
-1.2022
ネットキャッシュフロー:
$-328.09M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+6.14%
6か月 パフォーマンス:
-33.55%
1年 パフォーマンス:
-35.74%
1日の値動き範囲:
$3.07
$3.34
1週間の範囲:
$2.95
$3.39
52週間の値動き範囲:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.11 | 1.75B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed (RXRX) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI-Driven Drug Discovery Advances - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX: AI-driven platform advances multiple clinical programs with major data readouts expected soon - TradingView
Recursion Pharmaceuticals (RXRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Here’s Why Recursion Pharmaceuticals (RXRX) is Among the Best Penny Stocks - Insider Monkey
Recursion Pharmaceuticals Stock Surges After Consecutive Losses - asatunews.co.id
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceutica - GuruFocus
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock - Investing.com UK
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade - Stock Titan
Recursion Q1 2026 slides: pipeline advances amid revenue shortfall - Investing.com
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Najat Khan plans Rule 144 sale of Recursion (NASDAQ: RXRX) shares on 05/15/2026 - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway - Sahm
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Gibson files Form 144 to sell 40,000 Class A shares (RXRX) - Stock Titan
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bumpus Namandje - Moomoo
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business Updates - Insider Monkey
9 Stocks Crushing the Market With Surging Returns - Insider Monkey
Insider Sell: Namandje Bumpus Sells Shares of Recursion Pharmace - GuruFocus
10 Best Penny Stocks with Huge Upside Potential - Insider Monkey
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Recursion (NASDAQ: RXRX) director sells 30,000 shares under 10b5-1 plan - Stock Titan
RXRX Stock Grinds Higher As Earnings Beat Supports AI Drug Story - timothysykes.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Proof and AI Platform Advancements - Quiver Quantitative
RXRX Stock Climbs As Earnings Beat Highlights AI Drug Progress - StocksToTrade
Recursion Stock Jumps Before Goldman Sachs Event as AI-Drug Trade Gets Fresh Heat - TechStock²
RXRX Stock Climbs As Earnings Beat Extends Cash Runway - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results - Yahoo Finance
Earnings call transcript: Recursion Pharmaceuticals Q1 2026 results show EPS beat but revenue miss - Investing.com
Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation - Yahoo Finance
[144] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - MSN
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals to present at Goldman Sachs Healthcare Conference on June 9, 2026 - Pluang
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum - simplywall.st
RXRX (NASDAQ) affiliate sales reported: Borgeson sells 230,000 shares in 2026 - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
Recursion Pharmaceuticals Inc (RXRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Khan Najat | CEO and President |
Jun 05 '26 |
Sale |
3.58 |
23,588 |
84,459 |
2,175,796 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):